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Abstract
The availability of the human papillomavirus (HPV) vaccine has positioned primary care physicians
to play an active role in ensuring its successful implementation. However, physicians must be aware
of common knowledge, attitudes, and belief barriers associated with HPV and the vaccine that are
often encountered during clinical visits. This editorial provides primary care physicians an overview
of these barriers and realistic recommendations utilizing the "5A's" – Awareness, Assess, Address,
Acceptability, and Activate. This mnemonic can help facilitate a physician's systematic approach to
increasing HPV vaccination rates during the clinical encounter.
Human papillomavirus (HPV) is the most common sexu-
ally transmitted disease (STD) in the United States and the
predominant cause of cervical cancer and genital warts
[1,2]. In 2006, the United States Food and Drug Adminis-
tration approved the first HPV vaccine for females
between the ages of 9 and 26 to protect them against the
6,11,16,18 HPV strains. Phase II and III clinical trials have
shown the vaccine to be efficacious in preventing cyto-
logic abnormalities (cervical intraepithelial neoplasia I, II,
and III), genital warts, and vulvar or vaginal neoplasia [3-
5]. Prevention rates were high in these studies, ranging
from 89–100%. However, caution is advised in interpret-
ing these results and providing information to patients
and caregivers because of the short duration of the trials
(approximately 2 years). It remains unknown whether the
introduction of this vaccine will prevent future cervical
cancer cases and associated deaths. However, the strong
biologic plausibility encourages researchers, politicians,
and clinicians to implement HPV vaccination programs.
Primary care physicians (PCPs) are uniquely positioned to
deliver a HPV vaccination preventive strategy to their
communities since most preventive care services occur in
the outpatient setting. Unfortunately, one report esti-
mated 10% of females ages 18–26 have received at least
one dose of the vaccine [6]. The purpose of this editorial
is to provide recommendations to PCPs to overcome
potential interpersonal and clinical barriers associated
with HPV vaccination. While cost and access to care are
two system barriers associated with HPV vaccination, this
editorial focuses on qualitative factors that may be
encountered during a clinical visit. PCPs must be aware of
individual factors impeding successful HPV vaccination
programs in clinics and communities. Armed with this
knowledge, PCPs can mediate informational barriers and
misconceptions often associated with the HPV vaccine. A
shared-decision making and patient-centered approach is
recommended when introducing the HPV vaccine to
patients/caregivers.
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Osteopathic Medicine and Primary Care 2008, 2:10 http://www.om-pc.com/content/2/1/10Since the HPV vaccine is predominantly offered for
patients of younger ages, PCPs must be willing and able to
communicate with not only the patient, but, more impor-
tantly, the caregiver of the patient. Females under the age
of 18 receiving the vaccination must be accompanied by a
parent to provide informed consent. Hence, it is not sur-
prising that several barriers are associated with concerns,
beliefs, and knowledge deficits of the parent or caregiver.
One concern is that receiving the HPV vaccination may
"condone" risky sexual behaviors among young females
[7]. In reality, studies have shown that only 6–12% of car-
egivers are actually concerned about this issue [8-11].
Research also reports that teenage girls were no more
interested in risky behavior if they were to receive the vac-
cination [12]. PCPs must remember to educate caregivers
and patients that the vaccine does not protect them from
other STDs and other strains of the HPV and that safe sex
practices and screening Papanicolaou tests must always be
followed. Caregivers do not see a need for the HPV vacci-
nation if they believe their child is not sexually active [10].
In this instance, the PCP should emphasize that the ideal
time to administer the vaccine is prior to sexual initiation.
The patient/caregiver must be aware the HPV vaccine is
not currently approved for males. Although this may
change as more evidence accrues, the principle of preven-
tion must be emphasized with patients and caregivers.
A decision to not receive the HPV vaccine may also be due
to religious/spiritual factors [13]. Regardless, the PCP
should be aware that patients and caregivers are accepting
of vaccination and the PCP should still inform them
about the availability of the vaccine and its benefits and
risks (e.g., pain, discomfort, allergic reaction). In fact, risks
are a frequent concern that patients express as they want
to be educated about the vaccine's safety [14]. The trials
have found the vaccine to be safe, with pain and discom-
fort at the injection site being the most common com-
plaints [5]. Long term consequences are undetermined
due to the recent introduction of the vaccine. Patients and
caregivers also want to know if the vaccine actually works
and PCPs must be prepared to provide this information
[5]. As stated previously, although the vaccine has been
shown to prevent 89–100% of cytologic abnormalities,
genital warts, and vulvar or vaginal neoplasia several years
after the completion of the series [3-5], patients and car-
egivers must also be informed that long term outcomes
remain unknown.
While PCPs routinely educate patients during clinical vis-
its, it becomes even more important when discussing HPV
and the vaccination. Studies have shown that the public is
largely unaware of HPV, its consequences, and the availa-
bility of a vaccine [15]. This is especially true for different
racial/ethnic groups and PCPs must be proactive in estab-
lishing a successful HPV vaccination program in their
clinic. A major barrier to successful vaccination programs
is that teenagers do not frequently seek preventive visits
[16]. Therefore, PCPs must offer the vaccination during
other office visits, such as acute visits. It is important to
inform patients/caregivers that the HPV vaccination is a 3
injection series (0, 2, 6 months) and that compliance is
extremely important for the vaccine to take effect. Patients
and caregivers must take responsibility for following up
for remaining injections. However, automatic reminders
or other system measures are usually necessary to achieve
high completion rates. PCPs should consider utilizing
vaccination flow sheets, call-back reminders, or other
interventions that are simple, effective, and sustainable.
The most important factor in receiving the HPV vaccina-
tion is for the PCP to discuss and offer it to eligible
patients [17,18]. As mentioned earlier, PCPs need to take
an active role for HPV vaccination rates to increase. Wait-
ing for patients and caregivers to inquire about the HPV
vaccine will only have a negligible impact on the rates. To
assist PCPs in becoming active leaders in successful clini-
cal HPV vaccination programs, the authors recommend
remembering the "5 A's":
Awareness – Ask patients/caregivers what they know
about HPV, its causes, and their knowledge about an
available vaccine. PCPs must be vigilant in initiating dis-
cussions and offering the vaccine to eligible patients.
Assess – Inquire about any concerns related to the vac-
cine's safety, side-effects, efficacy and effectiveness, and
potential changes in risky sexual behaviors.
Address – Provide explanations and evidence-based infor-
mation using easy-to-understand language. Be proactive
in providing reassuring information even if not asked or
expressed by patients/caregivers.
Acceptability – Once the PCP assesses and addresses any
issues or concerns expressed by the patient/caregiver, the
PCP needs to determine whether the HPV vaccine is
acceptable to the patient/caregiver in the context of cost,
insurance coverage, religious/spiritual determinants, or
any other factors.
Activate – Once the PCP and the patient/caregiver have
jointly determined an acceptable plan, the first of 3 injec-
tions should be given. The PCP must emphasize the
importance of completing the 3 dose vaccination series
and, if possible, develop a plan to help themself and the
patient/caregiver remember follow-up dates.
Effective office-based HPV vaccination programs involve
an integrated team approach that is activated by both phy-Page 2 of 3
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sicians and patients/caregivers. Successful national child-
hood vaccination programs should serve as models for
HPV vaccination programs. Cost, attitudes, beliefs, and
targeted demographics related to the HPV vaccine make
the challenges unique. However, dedicated efforts by phy-
sicians and staff can be effective in overcoming such chal-
lenges.
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